Prognostic factors in methylprednisolone pulse therapy for alopecia areata

Journal of Dermatology

Volumn 38, Issue 8, 2011, Pages 767-772

  Im, Myung ^a,b   Lee, Sang Sin ^a   Lee, Young ^a   Kim, Chang Deok ^a   Seo, Young Joon ^a   Lee, Jeung Hoon ^a   Park, Jang Kyu ^a  

^a Chungnam National University College of Medicine   (South Korea)

^b Well Dermatology and Laser Clinic   (South Korea)

Author keywords

alopecia areata; duration; methylprednisolone; prognostic factor; pulse therapy

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ALOPECIA AREATA; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG PULSE THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR GROWTH; HAIR LOSS; HEADACHE; HEART PALPITATION; HUMAN; HYPERTRICHOSIS; MAJOR CLINICAL STUDY; MALASSEZIA DERMATITIS; MALE; MOON FACE; OUTCOME ASSESSMENT; PROGNOSIS; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALOPECIA AREATA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961031694     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01135.x     Document Type: Article

References (14)

1. Safavi KHH, Muller SA, Suman VJ, Moshell AN, Melton LJ,. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70: 628-633.
2. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG,. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-699. (Pubitemid 37419985)
3. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A,. Alopecia areata. Int J Dermatol 2007; 46: 121-131. (Pubitemid 46679412)
4. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J,. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62: 177-188.
5. Winter RJ, Kern F, Blizzard RM,. Prednisone therapy for alopecia areata. Arch Dermatol 1976; 112: 1549-1552.
6. Burton JL, Shuster S,. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975; 55: 493-496.
7. Nakajima T, Inui S, Itami S,. Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology 2007; 215: 320-324. (Pubitemid 47519261)
8. Fisher DA,. Systemic steroids in the treatment of alopecia areata. Arch Dermatol 1977; 113: 1731-1732. (Pubitemid 8241744)
9. Wolverton SE,. Glucocorticoid. In:, Wolverton SE, Wilkin JK, eds. Systemic Drug for Skin Disease. Philadelphia: WB Saunders Company, 1991; 86-124.
10. Wolfensberger JP, Koo FP, Marinetti C, et al. Pulse of methylprednisolone in alopecia areata. Dermatol 1993; 187: 282-285.
11. Simone S, Selma U, Wolfgang T, Uwe R,. High dose pulse corticosteroid in therapy in the treatment of severe alopecia areata. Dermatol 2001; 202: 230-234.
12. Assouly P, Reygagne P, Jouanique C, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients. Ann Dermatol Venereol 2003; 130: 326-330. (Pubitemid 36542233)
13. Abell E, Gruber HM,. A histopathologic reappraisal of alopecia areata. J Cutan Pathol 1987; 14: 347.
14. Van der Steen PH, van Baar HM, Happle R, Boezeman JB, Perret CM,. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24: 227-230.